25 XP   0   0   10

Jafron Biomedical Co Ltd
Buy, Hold or Sell?

Let's analyse Jafron Biomedical Co Ltd together

PenkeI guess you are interested in Jafron Biomedical Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Jafron Biomedical Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Jafron Biomedical Co Ltd

I send you an email if I find something interesting about Jafron Biomedical Co Ltd.

Quick analysis of Jafron Biomedical Co Ltd (30 sec.)










What can you expect buying and holding a share of Jafron Biomedical Co Ltd? (30 sec.)

How much money do you get?

How much money do you get?
¥0.50
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
¥4.45
Expected worth in 1 year
¥5.47
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
¥4.63
Return On Investment
20.9%

For what price can you sell your share?

Current Price per Share
¥22.16
Expected price per share
¥19.37 - ¥24.93
How sure are you?
50%

1. Valuation of Jafron Biomedical Co Ltd (5 min.)




Live pricePrice per Share (EOD)

¥22.16

Intrinsic Value Per Share

¥3.29 - ¥9.18

Total Value Per Share

¥7.74 - ¥13.63

2. Growth of Jafron Biomedical Co Ltd (5 min.)




Is Jafron Biomedical Co Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$496.2m$467.6m$28.5m5.8%

How much money is Jafron Biomedical Co Ltd making?

Current yearPrevious yearGrowGrow %
Making money$122.9m$165.3m-$42.4m-34.5%
Net Profit Margin35.7%44.7%--

How much money comes from the company's main activities?

3. Financial Health of Jafron Biomedical Co Ltd (5 min.)




4. Comparing to competitors in the Medical Devices industry (5 min.)




  Industry Rankings (Medical Devices)  


Richest
#56 / 339

Most Revenue
#45 / 339

Most Profit
#20 / 339

What can you expect buying and holding a share of Jafron Biomedical Co Ltd? (5 min.)

Welcome investor! Jafron Biomedical Co Ltd's management wants to use your money to grow the business. In return you get a share of Jafron Biomedical Co Ltd.

What can you expect buying and holding a share of Jafron Biomedical Co Ltd?

First you should know what it really means to hold a share of Jafron Biomedical Co Ltd. And how you can make/lose money.

Speculation

The Price per Share of Jafron Biomedical Co Ltd is ¥22.16. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Jafron Biomedical Co Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Jafron Biomedical Co Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥4.45. Based on the TTM, the Book Value Change Per Share is ¥0.26 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.68 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.90 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Jafron Biomedical Co Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.150.7%0.150.7%0.200.9%0.130.6%0.080.4%
Usd Book Value Change Per Share0.040.2%0.040.2%0.090.4%0.080.3%0.060.3%
Usd Dividend Per Share0.120.6%0.120.6%0.090.4%0.070.3%0.040.2%
Usd Total Gains Per Share0.160.7%0.160.7%0.190.8%0.140.7%0.100.4%
Usd Price Per Share4.28-4.28-7.37-7.34-4.76-
Price to Earnings Ratio28.12-28.12-35.96-62.33-59.02-
Price-to-Total Gains Ratio26.74-26.74-39.82-54.48-59.28-
Price to Book Ratio6.97-6.97-12.72-17.04-13.58-
Price-to-Total Gains Ratio26.74-26.74-39.82-54.48-59.28-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.062512
Number of shares326
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.120.07
Usd Book Value Change Per Share0.040.08
Usd Total Gains Per Share0.160.14
Gains per Quarter (326 shares)52.1947.24
Gains per Year (326 shares)208.74188.95
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1163461999198179
232592408182196368
3488138617273294557
4651184826363392746
58142301035454491935
697627612445455891124
7113932214536366871313
8130236816627277851502
9146541418718188831691
10162746020809089811880

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%8.00.02.080.0%8.00.04.066.7%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%12.00.00.0100.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%12.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%12.00.00.0100.0%

Fundamentals of Jafron Biomedical Co Ltd

About Jafron Biomedical Co Ltd

Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sales of blood purification products for hemadsorption industry in China and internationally. The company offers solutions for ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, kidney, and liver diseases; HA series hemoperfusion cartridge, BS bilirubin adsorption column and DNA immunoadsorption column, hemoperfusion machine, and blood purification machine; and other products, such as hemodialyzer, hemodialysis concentrate, disinfectants, resin bandages, online hemodialysis powder bag/bucket, and adsorbable suture with needles. The company was founded in 1989 and is based in Zhuhai, China.

Fundamental data was last updated by Penke on 2024-04-16 15:52:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is overpriced.

1.1. Profitability of Jafron Biomedical Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Jafron Biomedical Co Ltd earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Jafron Biomedical Co Ltd to the Medical Devices industry mean.
  • A Net Profit Margin of 35.7% means that ¥0.36 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Jafron Biomedical Co Ltd:

  • The MRQ is 35.7%. The company is making a huge profit. +2
  • The TTM is 35.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ35.7%TTM35.7%0.0%
TTM35.7%YOY44.7%-9.0%
TTM35.7%5Y40.9%-5.2%
5Y40.9%10Y32.1%+8.9%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ35.7%-11.2%+46.9%
TTM35.7%-19.6%+55.3%
YOY44.7%-14.4%+59.1%
5Y40.9%-21.3%+62.2%
10Y32.1%-24.8%+56.9%
1.1.2. Return on Assets

Shows how efficient Jafron Biomedical Co Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Jafron Biomedical Co Ltd to the Medical Devices industry mean.
  • 16.4% Return on Assets means that Jafron Biomedical Co Ltd generated ¥0.16 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Jafron Biomedical Co Ltd:

  • The MRQ is 16.4%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 16.4%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ16.4%TTM16.4%0.0%
TTM16.4%YOY24.9%-8.4%
TTM16.4%5Y22.2%-5.8%
5Y22.2%10Y17.2%+5.0%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ16.4%-4.0%+20.4%
TTM16.4%-4.5%+20.9%
YOY24.9%-4.8%+29.7%
5Y22.2%-4.0%+26.2%
10Y17.2%-4.9%+22.1%
1.1.3. Return on Equity

Shows how efficient Jafron Biomedical Co Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Jafron Biomedical Co Ltd to the Medical Devices industry mean.
  • 24.9% Return on Equity means Jafron Biomedical Co Ltd generated ¥0.25 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Jafron Biomedical Co Ltd:

  • The MRQ is 24.9%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 24.9%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ24.9%TTM24.9%0.0%
TTM24.9%YOY35.6%-10.7%
TTM24.9%5Y28.4%-3.5%
5Y28.4%10Y21.5%+6.9%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ24.9%-3.9%+28.8%
TTM24.9%-5.6%+30.5%
YOY35.6%-5.9%+41.5%
5Y28.4%-6.1%+34.5%
10Y21.5%-7.0%+28.5%

1.2. Operating Efficiency of Jafron Biomedical Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Jafron Biomedical Co Ltd is operating .

  • Measures how much profit Jafron Biomedical Co Ltd makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Jafron Biomedical Co Ltd to the Medical Devices industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Jafron Biomedical Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY49.5%-49.5%
TTM-5Y36.3%-36.3%
5Y36.3%10Y31.4%+4.9%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ--24.1%+24.1%
TTM--16.9%+16.9%
YOY49.5%-13.4%+62.9%
5Y36.3%-19.2%+55.5%
10Y31.4%-24.0%+55.4%
1.2.2. Operating Ratio

Measures how efficient Jafron Biomedical Co Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Devices industry mean).
  • An Operation Ratio of 0.77 means that the operating costs are ¥0.77 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Jafron Biomedical Co Ltd:

  • The MRQ is 0.773. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.773. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.773TTM0.7730.000
TTM0.773YOY0.634+0.140
TTM0.7735Y0.690+0.083
5Y0.69010Y0.595+0.095
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7731.431-0.658
TTM0.7731.426-0.653
YOY0.6341.503-0.869
5Y0.6901.440-0.750
10Y0.5951.371-0.776

1.3. Liquidity of Jafron Biomedical Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Jafron Biomedical Co Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Devices industry mean).
  • A Current Ratio of 4.59 means the company has ¥4.59 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Jafron Biomedical Co Ltd:

  • The MRQ is 4.592. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.592. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.592TTM4.5920.000
TTM4.592YOY7.911-3.319
TTM4.5925Y5.825-1.233
5Y5.82510Y5.003+0.822
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ4.5922.754+1.838
TTM4.5922.763+1.829
YOY7.9113.488+4.423
5Y5.8253.617+2.208
10Y5.0033.514+1.489
1.3.2. Quick Ratio

Measures if Jafron Biomedical Co Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Jafron Biomedical Co Ltd to the Medical Devices industry mean.
  • A Quick Ratio of 0.31 means the company can pay off ¥0.31 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Jafron Biomedical Co Ltd:

  • The MRQ is 0.309. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.309. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.309TTM0.3090.000
TTM0.309YOY1.202-0.893
TTM0.3095Y0.635-0.325
5Y0.63510Y0.731-0.097
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3091.532-1.223
TTM0.3091.656-1.347
YOY1.2022.139-0.937
5Y0.6352.301-1.666
10Y0.7312.255-1.524

1.4. Solvency of Jafron Biomedical Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Jafron Biomedical Co Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Jafron Biomedical Co Ltd to Medical Devices industry mean.
  • A Debt to Asset Ratio of 0.34 means that Jafron Biomedical Co Ltd assets are financed with 33.7% credit (debt) and the remaining percentage (100% - 33.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Jafron Biomedical Co Ltd:

  • The MRQ is 0.337. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.337. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.337TTM0.3370.000
TTM0.337YOY0.297+0.040
TTM0.3375Y0.209+0.128
5Y0.20910Y0.183+0.025
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3370.389-0.052
TTM0.3370.386-0.049
YOY0.2970.338-0.041
5Y0.2090.442-0.233
10Y0.1830.460-0.277
1.4.2. Debt to Equity Ratio

Measures if Jafron Biomedical Co Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Jafron Biomedical Co Ltd to the Medical Devices industry mean.
  • A Debt to Equity ratio of 51.0% means that company has ¥0.51 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Jafron Biomedical Co Ltd:

  • The MRQ is 0.510. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.510. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.510TTM0.5100.000
TTM0.510YOY0.425+0.085
TTM0.5105Y0.283+0.227
5Y0.28310Y0.237+0.047
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5100.559-0.049
TTM0.5100.560-0.050
YOY0.4250.478-0.053
5Y0.2830.624-0.341
10Y0.2370.674-0.437

2. Market Valuation of Jafron Biomedical Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Jafron Biomedical Co Ltd generates.

  • Above 15 is considered overpriced but always compare Jafron Biomedical Co Ltd to the Medical Devices industry mean.
  • A PE ratio of 28.12 means the investor is paying ¥28.12 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Jafron Biomedical Co Ltd:

  • The EOD is 20.122. Based on the earnings, the company is fair priced.
  • The MRQ is 28.121. Based on the earnings, the company is overpriced. -1
  • The TTM is 28.121. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD20.122MRQ28.121-8.000
MRQ28.121TTM28.1210.000
TTM28.121YOY35.964-7.843
TTM28.1215Y62.333-34.212
5Y62.33310Y59.021+3.312
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD20.122-0.997+21.119
MRQ28.121-1.578+29.699
TTM28.121-2.041+30.162
YOY35.964-2.761+38.725
5Y62.333-2.064+64.397
10Y59.021-1.463+60.484
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Jafron Biomedical Co Ltd:

  • The EOD is 43.879. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 61.324. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 61.324. Based on how much money comes from the company's main activities, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD43.879MRQ61.324-17.445
MRQ61.324TTM61.3240.000
TTM61.324YOY60.453+0.871
TTM61.3245Y106.414-45.090
5Y106.41410Y98.919+7.495
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD43.879-0.935+44.814
MRQ61.324-1.489+62.813
TTM61.324-2.994+64.318
YOY60.453-6.238+66.691
5Y106.414-4.771+111.185
10Y98.919-4.736+103.655
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Jafron Biomedical Co Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Devices industry mean).
  • A PB ratio of 6.97 means the investor is paying ¥6.97 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Jafron Biomedical Co Ltd:

  • The EOD is 4.985. Based on the equity, the company is fair priced.
  • The MRQ is 6.967. Based on the equity, the company is overpriced. -1
  • The TTM is 6.967. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD4.985MRQ6.967-1.982
MRQ6.967TTM6.9670.000
TTM6.967YOY12.721-5.754
TTM6.9675Y17.041-10.074
5Y17.04110Y13.580+3.461
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD4.9851.890+3.095
MRQ6.9672.379+4.588
TTM6.9672.458+4.509
YOY12.7213.214+9.507
5Y17.0413.833+13.208
10Y13.5804.173+9.407
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Jafron Biomedical Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.2550.2550%0.681-63%0.544-53%0.409-38%
Book Value Per Share--4.4454.4450%4.190+6%3.393+31%2.188+103%
Current Ratio--4.5924.5920%7.911-42%5.825-21%5.003-8%
Debt To Asset Ratio--0.3370.3370%0.297+14%0.209+61%0.183+84%
Debt To Equity Ratio--0.5100.5100%0.425+20%0.283+80%0.237+116%
Dividend Per Share--0.9030.9030%0.658+37%0.504+79%0.299+202%
Eps--1.1011.1010%1.482-26%0.974+13%0.572+92%
Free Cash Flow Per Share--0.5050.5050%0.882-43%0.568-11%0.354+43%
Free Cash Flow To Equity Per Share--0.5050.5050%1.086-54%0.455+11%0.345+46%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.800+25%
Intrinsic Value_10Y_max--9.183--------
Intrinsic Value_10Y_min--3.291--------
Intrinsic Value_1Y_max--0.757--------
Intrinsic Value_1Y_min--0.351--------
Intrinsic Value_3Y_max--2.399--------
Intrinsic Value_3Y_min--1.043--------
Intrinsic Value_5Y_max--4.191--------
Intrinsic Value_5Y_min--1.716--------
Market Cap17895418977.280-40%25014790654.42025014790654.4200%43042681926.400-42%42870827566.020-42%27810253016.162-10%
Net Profit Margin--0.3570.3570%0.447-20%0.409-13%0.321+11%
Operating Margin----0%0.495-100%0.363-100%0.314-100%
Operating Ratio--0.7730.7730%0.634+22%0.690+12%0.595+30%
Pb Ratio4.985-40%6.9676.9670%12.721-45%17.041-59%13.580-49%
Pe Ratio20.122-40%28.12128.1210%35.964-22%62.333-55%59.021-52%
Price Per Share22.160-40%30.97030.9700%53.300-42%53.086-42%34.437-10%
Price To Free Cash Flow Ratio43.879-40%61.32461.3240%60.453+1%106.414-42%98.919-38%
Price To Total Gains Ratio19.131-40%26.73726.7370%39.816-33%54.483-51%59.285-55%
Quick Ratio--0.3090.3090%1.202-74%0.635-51%0.731-58%
Return On Assets--0.1640.1640%0.249-34%0.222-26%0.172-5%
Return On Equity--0.2490.2490%0.356-30%0.284-12%0.215+16%
Total Gains Per Share--1.1581.1580%1.339-13%1.048+10%0.708+64%
Usd Book Value--496200327.998496200327.9980%467619814.146+6%378672360.618+31%244231481.889+103%
Usd Book Value Change Per Share--0.0350.0350%0.094-63%0.075-53%0.056-38%
Usd Book Value Per Share--0.6140.6140%0.579+6%0.469+31%0.302+103%
Usd Dividend Per Share--0.1250.1250%0.091+37%0.070+79%0.041+202%
Usd Eps--0.1520.1520%0.205-26%0.135+13%0.079+92%
Usd Free Cash Flow--56373615.29256373615.2920%98398805.576-43%63396896.075-11%39484219.288+43%
Usd Free Cash Flow Per Share--0.0700.0700%0.122-43%0.079-11%0.049+43%
Usd Free Cash Flow To Equity Per Share--0.0700.0700%0.150-54%0.063+11%0.048+46%
Usd Market Cap2473146902.660-40%3457044068.4413457044068.4410%5948498642.228-42%5924748369.624-42%3843376966.834-10%
Usd Price Per Share3.063-40%4.2804.2800%7.366-42%7.336-42%4.759-10%
Usd Profit--122934110.810122934110.8100%165399605.584-26%108746657.594+13%63867302.886+92%
Usd Revenue--344316929.516344316929.5160%369747806.395-7%264404310.893+30%165997263.216+107%
Usd Total Gains Per Share--0.1600.1600%0.185-13%0.145+10%0.098+64%
 EOD+4 -4MRQTTM+0 -0YOY+8 -275Y+17 -1810Y+23 -13

3.2. Fundamental Score

Let's check the fundamental score of Jafron Biomedical Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1520.122
Price to Book Ratio (EOD)Between0-14.985
Net Profit Margin (MRQ)Greater than00.357
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.309
Current Ratio (MRQ)Greater than14.592
Debt to Asset Ratio (MRQ)Less than10.337
Debt to Equity Ratio (MRQ)Less than10.510
Return on Equity (MRQ)Greater than0.150.249
Return on Assets (MRQ)Greater than0.050.164
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Jafron Biomedical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.990
Ma 20Greater thanMa 5022.705
Ma 50Greater thanMa 10021.647
Ma 100Greater thanMa 20021.577
OpenGreater thanClose22.400
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets5,413,416
Total Liabilities1,822,965
Total Stockholder Equity3,574,282
 As reported
Total Liabilities 1,822,965
Total Stockholder Equity+ 3,574,282
Total Assets = 5,413,416

Assets

Total Assets5,413,416
Total Current Assets3,293,248
Long-term Assets2,120,168
Total Current Assets
Cash And Cash Equivalents 2,558,755
Net Receivables 221,727
Inventory 349,130
Other Current Assets 35,646
Total Current Assets  (as reported)3,293,248
Total Current Assets  (calculated)3,165,259
+/- 127,989
Long-term Assets
Property Plant Equipment 1,671,903
Goodwill 37,814
Intangible Assets 100,431
Long-term Assets Other 148,216
Long-term Assets  (as reported)2,120,168
Long-term Assets  (calculated)1,958,364
+/- 161,803

Liabilities & Shareholders' Equity

Total Current Liabilities717,182
Long-term Liabilities1,105,783
Total Stockholder Equity3,574,282
Total Current Liabilities
Short Long Term Debt 317,090
Accounts payable 128,522
Other Current Liabilities 5,475
Total Current Liabilities  (as reported)717,182
Total Current Liabilities  (calculated)451,087
+/- 266,094
Long-term Liabilities
Long term Debt 936,783
Capital Lease Obligations Min Short Term Debt17,344
Long-term Liabilities  (as reported)1,105,783
Long-term Liabilities  (calculated)954,127
+/- 151,656
Total Stockholder Equity
Retained Earnings 2,102,661
Total Stockholder Equity (as reported)3,574,282
Total Stockholder Equity (calculated)2,102,661
+/- 1,471,621
Other
Capital Stock807,710
Common Stock Shares Outstanding 807,710
Net Invested Capital 4,828,156
Net Working Capital 2,576,066
Property Plant and Equipment Gross 1,900,563



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-31
> Total Assets 
246,241
341,579
461,727
539,013
688,675
1,299,867
1,702,400
2,051,958
2,494,662
3,216,670
4,810,102
5,413,416
5,413,4164,810,1023,216,6702,494,6622,051,9581,702,4001,299,867688,675539,013461,727341,579246,241
   > Total Current Assets 
0
0
0
0
400,185
999,201
1,230,659
1,305,242
1,559,744
1,986,611
3,055,652
3,293,248
3,293,2483,055,6521,986,6111,559,7441,305,2421,230,659999,201400,1850000
       Cash And Cash Equivalents 
175,282
217,356
248,369
232,850
287,487
760,084
1,061,659
1,080,802
1,271,730
1,575,050
2,319,448
2,558,755
2,558,7552,319,4481,575,0501,271,7301,080,8021,061,659760,084287,487232,850248,369217,356175,282
       Short-term Investments 
0
0
0
0
0
100,000
0
0
0
0
150,015
0
0150,0150000100,00000000
       Net Receivables 
8,378
8,698
13,061
37,073
57,316
81,798
109,227
141,946
169,823
167,407
314,372
221,727
221,727314,372167,407169,823141,946109,22781,79857,31637,07313,0618,6988,378
       Other Current Assets 
8,855
4,357
11,225
5,926
16,371
6,836
14,536
21,336
25,877
65,307
75,270
35,646
35,64675,27065,30725,87721,33614,5366,83616,3715,92611,2254,3578,855
   > Long-term Assets 
0
0
0
0
0
300,666
471,741
746,716
934,918
1,230,059
1,754,450
2,120,168
2,120,1681,754,4501,230,059934,918746,716471,741300,66600000
       Property Plant Equipment 
14,729
66,325
135,032
201,283
260,164
273,324
325,547
457,622
639,629
905,505
1,272,529
1,671,903
1,671,9031,272,529905,505639,629457,622325,547273,324260,164201,283135,03266,32514,729
       Goodwill 
0
0
7,011
7,011
7,011
7,011
17,718
44,070
44,070
44,070
44,070
37,814
37,81444,07044,07044,07044,07017,7187,0117,0117,0117,01100
       Long Term Investments 
0
0
0
0
0
0
0
90,566
0
0
0
0
000090,5660000000
       Intangible Assets 
16,594
16,469
23,149
23,733
17,474
17,143
30,912
46,587
48,051
89,889
101,313
100,431
100,431101,31389,88948,05146,58730,91217,14317,47423,73323,14916,46916,594
       Long-term Assets Other 
0
0
0
0
0
1,236
92,086
97,356
77,491
58,218
162,765
148,216
148,216162,76558,21877,49197,35692,0861,23600000
> Total Liabilities 
30,676
50,740
81,602
86,590
124,611
115,812
310,904
330,042
324,127
383,060
1,426,457
1,822,965
1,822,9651,426,457383,060324,127330,042310,904115,812124,61186,59081,60250,74030,676
   > Total Current Liabilities 
28,526
36,951
53,290
53,618
89,157
84,286
269,843
278,899
262,633
330,817
386,260
717,182
717,182386,260330,817262,633278,899269,84384,28689,15753,61853,29036,95128,526
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
317,090
317,09000000000000
       Accounts payable 
4,639
6,514
5,882
9,788
28,407
19,949
25,646
29,897
32,831
50,216
60,760
128,522
128,52260,76050,21632,83129,89725,64619,94928,4079,7885,8826,5144,639
       Other Current Liabilities 
23,887
30,436
47,408
43,830
28,827
33,458
188,683
166,200
131,803
140,814
129,347
5,475
5,475129,347140,814131,803166,200188,68333,45828,82743,83047,40830,43623,887
   > Long-term Liabilities 
0
0
0
0
0
31,525
41,060
51,143
61,494
52,244
1,040,197
1,105,783
1,105,7831,040,19752,24461,49451,14341,06031,52500000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
11,766
17,012
17,344
17,34417,01211,766000000000
       Deferred Long Term Liability 
0
0
0
0
3,017
853
3,456
3,362
14,819
20,418
35,952
0
035,95220,41814,8193,3623,4568533,0170000
> Total Stockholder Equity
215,566
290,840
380,124
452,423
564,064
1,184,055
1,391,088
1,698,479
2,142,470
2,806,790
3,358,858
3,574,282
3,574,2823,358,8582,806,7902,142,4701,698,4791,391,0881,184,055564,064452,423380,124290,840215,566
   Common Stock
75,000
75,000
135,000
370,000
370,000
412,000
416,604
417,276
418,663
799,109
805,497
0
0805,497799,109418,663417,276416,604412,000370,000370,000135,00075,00075,000
   Retained Earnings 
76,440
151,714
240,999
82,297
193,938
396,056
597,149
852,974
1,172,787
1,670,219
2,336,017
2,102,661
2,102,6612,336,0171,670,2191,172,787852,974597,149396,056193,93882,297240,999151,71476,440
   Capital Surplus 000000000000
   Treasury Stock00000-137,936000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
4,617
3,084
123,139
0
0123,1393,0844,61700000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,951,720
Cost of Revenue-388,856
Gross Profit1,562,8631,562,863
 
Operating Income (+$)
Gross Profit1,562,863
Operating Expense-1,468,687
Operating Income483,03394,177
 
Operating Expense (+$)
Research Development267,981
Selling General Administrative733,150
Selling And Marketing Expenses-
Operating Expense1,468,6871,001,131
 
Net Interest Income (+$)
Interest Income23,932
Interest Expense-61,520
Other Finance Cost-64,180
Net Interest Income26,592
 
Pretax Income (+$)
Operating Income483,033
Net Interest Income26,592
Other Non-Operating Income Expenses-
Income Before Tax (EBT)499,728483,033
EBIT - interestExpense = -61,520
439,742
501,262
Interest Expense61,520
Earnings Before Interest and Taxes (EBIT)-561,249
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax499,728
Tax Provision-67,477
Net Income From Continuing Ops432,251432,251
Net Income439,742
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--26,592
 

Technical Analysis of Jafron Biomedical Co Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Jafron Biomedical Co Ltd. The general trend of Jafron Biomedical Co Ltd is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Jafron Biomedical Co Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Jafron Biomedical Co Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 24.52 < 24.55 < 24.93.

The bearish price targets are: 21.86 > 21.75 > 19.37.

Tweet this
Jafron Biomedical Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Jafron Biomedical Co Ltd. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Jafron Biomedical Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Jafron Biomedical Co Ltd. The current macd is 0.13275614.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Jafron Biomedical Co Ltd price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Jafron Biomedical Co Ltd. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Jafron Biomedical Co Ltd price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Jafron Biomedical Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartJafron Biomedical Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Jafron Biomedical Co Ltd. The current adx is 20.39.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Jafron Biomedical Co Ltd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Jafron Biomedical Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Jafron Biomedical Co Ltd. The current sar is 23.85.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Jafron Biomedical Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Jafron Biomedical Co Ltd. The current rsi is 46.99. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Jafron Biomedical Co Ltd Daily Relative Strength Index (RSI) ChartJafron Biomedical Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Jafron Biomedical Co Ltd. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Jafron Biomedical Co Ltd price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Jafron Biomedical Co Ltd Daily Stochastic Oscillator ChartJafron Biomedical Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Jafron Biomedical Co Ltd. The current cci is -76.16494319.

Jafron Biomedical Co Ltd Daily Commodity Channel Index (CCI) ChartJafron Biomedical Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Jafron Biomedical Co Ltd. The current cmo is -14.57885718.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Jafron Biomedical Co Ltd Daily Chande Momentum Oscillator (CMO) ChartJafron Biomedical Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Jafron Biomedical Co Ltd. The current willr is -89.35483871.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Jafron Biomedical Co Ltd Daily Williams %R ChartJafron Biomedical Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Jafron Biomedical Co Ltd.

Jafron Biomedical Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Jafron Biomedical Co Ltd. The current atr is 0.83764824.

Jafron Biomedical Co Ltd Daily Average True Range (ATR) ChartJafron Biomedical Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Jafron Biomedical Co Ltd. The current obv is 602,538.

Jafron Biomedical Co Ltd Daily On-Balance Volume (OBV) ChartJafron Biomedical Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Jafron Biomedical Co Ltd. The current mfi is 52.96.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Jafron Biomedical Co Ltd Daily Money Flow Index (MFI) ChartJafron Biomedical Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Jafron Biomedical Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-23STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-24STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-11-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-08BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Jafron Biomedical Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Jafron Biomedical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.990
Ma 20Greater thanMa 5022.705
Ma 50Greater thanMa 10021.647
Ma 100Greater thanMa 20021.577
OpenGreater thanClose22.400
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Jafron Biomedical Co Ltd with someone you think should read this too:
  • Are you bullish or bearish on Jafron Biomedical Co Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Jafron Biomedical Co Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Jafron Biomedical Co Ltd

I send you an email if I find something interesting about Jafron Biomedical Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Jafron Biomedical Co Ltd.

Receive notifications about Jafron Biomedical Co Ltd in your mailbox!